Catalog No.: PC-22808Not For Human Use, Lab Use Only.
AZ-PRMT5i-1 is a potent, selective and MTA-cooperative PRMT5 inhibitor with IC50 of 5.5 nM in symmetrical dimethyl arginine methylation (SDMA) cellular imaging assay.
AZ-PRMT5i-1 is a potent, selective and MTA-cooperative PRMT5 inhibitor with IC50 of 5.5 nM in symmetrical dimethyl arginine methylation (SDMA) cellular imaging assay.
AZ-PRMT5i-1 has high selectivity for PRMT5 (as well as for the C449S mutant form of PRMT5) against a panel of 37 other lysine and arginine methyltransferases.
AZ-PRMT5i-1 has IC50 of 124 nM in MTAP-null LU99 lung cancer cells.
AZ-PRMT5i-1 selectively inhibits the proliferation of MTAP-deficient cancer cell lines versus cell lines that express MTAP.
AZ-PRMT5i-1 (50 mg/kg BID oral dose) exhibits strong tumor growth inhibition in MTAP-null LU99 xenograft model.
